NCT03970044View on ClinicalTrials.gov

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

PHASE4CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Exenatide 2 MG

Glucagon-like peptide-1 receptor

DRUG

Dapagliflozin 10 MG

sodium-glucose co-transporter 2 (SGLT2) inhibitor

Trial Locations (1)

78231

Consano Clinical Research, LLC, Shavano Park

Sponsors
All Listed Sponsors
lead

Consano Clinical Research, LLC

OTHER

NCT03970044 - Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept. | Biotech Hunter | Biotech Hunter